With the upcoming 2024 AACR Annual meeting in San Diego scheduled for 5 -10 April 2024, here is some background information:
AACR 2024 April 5-10, 2024 San Diego Convention Center, San Diego, California
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 52,000 members in 130 countries and territories. AACR's annual meeting attracts more than 21,000 participants from around the world and has been described as the "main forum to present and discuss cancer-related research." Attendees gather to discuss over 6,000 abstracts and to hear more than 250 invited presentations on significant discoveries in basic, clinical, and translational cancer research. Scientific award lectures, grant writing workshops, networking events, and educational sessions round out this comprehensive program.
AACR 2024 - American Association for Cancer Research (annual2024meeting.com)
This may have been posted previously... but from what I could find, the scheduled Imugene presentations at the AACR2024 Annual Meeting are as follows:
Session PO.CT02.01 - Phase II Clinical Trials 1
CT215 / 15 - Frontline vaccination with the Bcell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma - Final results from Phase II/HERIZON study
April 9, 2024, 9:00 AM - 12:30 PM Section 49
Presenter/Authors
J. Tobias , M. Kundi , E. Garner-Spitzer , C. Zielinski , M. Maglakelidze , Z. Andric , Z. Petrovic , R. Nagarkar , T.
Chawla , L. Chong , B. Nixon , S. Yavrom , N. J. Ede , U. Wiedermann ;
Medical University of Vienna, Vienna, Austria, ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia, Clinical Hospital
Center Bezanijska, Belgrade, Serbia, Military Medical Academy, Belgrade, Serbia, CG Manavata Cancer Centre,
Nashik, India, Tata Medical Center, Kolkata, India, Imugene Limited, Sydney, Australia
...
Abstract
Abstract is embargoed at this time.
Session PO.CT01.02 - First-in-Human Phase I Clinical Trials 2
CT182 / 10 - Oncolytic virus CF33-hNIS for the treatment of advanced cancer
April 9, 2024, 9:00 AM - 12:30 PM Section 48
Presenter/Authors
D. Li , A. F. Shields , H. Mamdani , P. Travis , G. Wright , W. Akerley , A. Spira , G. Daniels , J. Merchan , A. Kumar , E.
Lim , C. Egelston , O. Flores , S. Hamilton , J. Austria , A. Seiz , S. Yavrom , S. Fein , J. Byon , P. Woodard , G. A.
Wilkinson , J. Leddon ;
City of Hope Comprehensive Cancer Center, Duarte, CA, Barbara Ann Karmanos Cancer Institute, Detroit, MI,
Highlands Oncology, Fayetteville, AR, St Vincent's Hospital Melbourne, Melbourne, Australia, Huntsman Cancer
Institute, Salt Lake City, UT, New Experimental Therapeutics of Virginia - NEXT Oncology, Fairfax, VA, VA, University
of California San Diego, San Diego, CA, University of Miami, Miami, FL, University of Arizona, Tucson, AZ,
Spectrum Health Medical Group, Grand Rapids, MI, Imugene Ltd., Sydney, Australia, University of Cincinnati
Cancer Center, Cincinnati, OH
...
Abstract
Abstract is embargoed at this time.
Abstracts - The titles and text of the regular abstracts in Minisymposia and Poster Sessions, and the titles of the clinical trial and late-breaking abstracts, will be posted to the planner at 4:30 PM ET on Tuesday, March 5. The text of the clinical trial and late-breaking abstracts will be posted to the planner at 3:00 PM ET on Friday, April 5, the first day of the Annual Meeting.
Time Zones - Times for all sessions and presentations listed in this planner are in U.S. Pacific Time (PT).
Abstracts: AACR Annual Meeting 2024 Itinerary Planner | Home (abstractsonline.com)
Home: Abstracts | AACR Annual Meeting 2024 | AACR
- Forums
- ASX - By Stock
- IMU
- Why IMU is a multi multi bagger
Why IMU is a multi multi bagger, page-22148
-
-
- There are more pages in this discussion • 3,752 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
-0.002(2.78%) |
Mkt cap ! $385.8M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.2¢ | $41.09K | 776.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 2290050 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 562155 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 2290050 | 0.052 |
38 | 4333284 | 0.051 |
56 | 4598280 | 0.050 |
19 | 2213068 | 0.049 |
19 | 835580 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 562155 | 19 |
0.054 | 1359582 | 22 |
0.055 | 2171261 | 8 |
0.056 | 2745820 | 14 |
0.057 | 759484 | 9 |
Last trade - 10.46am 22/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |